A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 76
Summary
- Conditions
- Gastroesophageal Junction Cancer
- Cervical Cancer
- Esophageal Cancer
- Gastric Cancer
- Urothelial Carcinoma
- Hepatocellular Carcinoma
- Renal Cell Carcinoma
- Small Cell Lung Cancer
- Melanoma
- Merkel Cell Carcinoma
- RCC
- Mesothelioma
- Triple -Negative Breast Cancer
- Mismatch Repair Deficiency
- MSI
- Stomach Cancer
- Non -Small Cell Lung Cancer
- Ovarian Cancer
- Uveal Melanoma
- Squamous Cell Carcinoma of the Head and Neck
- NSCLC
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03652077
- Collaborators
- Not Provided
- Investigators
- Study Director: John Janik, MD Incyte Corporation
Get Well Soon